Skip to main content
๐ŸงฌPeptide Protocol Wiki

HGH Fragment 176-191: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 70 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides โ†’

โœ“Reviewed byEditorial Team
๐Ÿ“…Updated February 16, 2026
Unverified

๐Ÿ“ŒTL;DR

  • โ€ข4 community protocols documented
  • โ€ขEvidence level: Anecdotal Reports
  • โ€ขBased on 70 community reports
  • โ€ข3 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

AspectClinical ApproachCommunity ApproachSignificance
Relationship to AOD-9604AOD-9604 is a tyrosine-modified version of Fragment 176-191 that was developed for clinical trials. Published clinical data is primarily on AOD-9604, not the unmodified Fragment 176-191.Community uses both Fragment 176-191 and AOD-9604, sometimes interchangeably, though they are slightly different molecules. Fragment 176-191 tends to be more available from research peptide vendors.high

Most clinical trial data belongs to AOD-9604, not Fragment 176-191. The community applies AOD-9604 research results to Fragment 176-191 use, which may not be fully appropriate.

Clinical Trial ResultsThe largest AOD-9604 Phase IIb trial failed to achieve statistical significance for weight loss. A smaller trial showed modest fat loss at 1 mg daily. Development was terminated in 2007.Community interest persists despite the failed clinical trial. Users report subjective fat loss improvements, particularly when combined with diet and exercise protocols.high

The disconnect between failed clinical trial results and continued community interest is notable. Self-reported benefits may reflect diet/exercise changes or placebo effects.

Mechanism of Action SpecificityResearch indicates Fragment 176-191 stimulates lipolysis without affecting IGF-1 levels, glucose tolerance, or insulin resistance, suggesting a fat-specific mechanism.Community values the fat-specific mechanism and lack of GH-related side effects. Users emphasize that it does not affect blood sugar or promote tissue growth.low

Community understanding of the mechanism aligns well with published data. The selective lipolytic action without anabolic effects is accurately represented in community discussions.

Compare these community approaches with published research findings.

Community Protocols

Standard Fat Loss Protocol

Popular
Route
Subcutaneous
Dose
250-500 mcg
Frequency
1-2 times daily
Duration
4-8 weeks

Injected on empty stomach, typically AM fasted and/or pre-bed. Most common approach for fat loss.

Split Dose Protocol

Common
Route
Subcutaneous
Dose
250 mcg per injection
Frequency
Twice daily (AM fasted + pre-bed)
Duration
8-12 weeks

Total 500 mcg daily split between morning and evening; both injections should be on empty stomach

Higher Dose Protocol

Niche
Route
Subcutaneous
Dose
500-1000 mcg
Frequency
Once daily (AM fasted)
Duration
4-8 weeks

Some users report better results at higher doses; based on clinical trial data showing 1 mg effective dose

Frag + AOD-9604 Comparison

Niche
Route
Subcutaneous
Dose
300-500 mcg
Frequency
Once daily
Duration
8-12 weeks

Users sometimes alternate between or compare Fragment 176-191 and AOD-9604, which share similar active sequences

Stacking Patterns

HGH Fragment + CJC-1295/Ipamorelin

Common

Fat-specific lipolysis from the fragment combined with full GH secretagogue effects from the CJC/Ipa stack for comprehensive body composition improvement

hgh-fragment-176-191cjc-1295-no-dacipamorelin

HGH Fragment + AOD-9604

Niche

Dual lipolytic peptide approach; though similar in structure, some users report different subjective effects from each peptide

hgh-fragment-176-191aod-9604

HGH Fragment + Tesamorelin

Niche

Combines fragment-specific fat metabolism with tesamorelin GHRH-mediated visceral fat reduction for targeted fat loss

hgh-fragment-176-191tesamorelin

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 70+ self-experimenters report. Free with email.

150+ peptide profiles ยท 30+ comparisons ยท 18 research tools

Already subscribed?

Sources

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for HGH Fragment 176-191. The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.

HGH Fragment 176-191 is a peptide fragment corresponding to the lipolytic (fat-metabolizing) region of human growth hormone. It is used in the community primarily for targeted fat loss without the anabolic or diabetogenic effects of full-length GH.

Understanding Protocol Divergence#

Fragment vs AOD-9604 Confusion#

A significant source of confusion in the community is the relationship between HGH Fragment 176-191 and AOD-9604. Most published clinical data belongs to AOD-9604 (a tyrosine-modified version), but the community often applies these results to the unmodified fragment. Users should be aware that these are slightly different molecules with potentially different pharmacokinetic profiles.

Failed Clinical Trial Context#

The largest AOD-9604 clinical trial failed to achieve statistical significance for weight loss, and development was terminated in 2007. Despite this, community interest persists, with users reporting subjective fat loss improvements. This disconnect between clinical trial failure and continued community enthusiasm should be considered when evaluating community reports.

Commonly Reported Outcomes#

Community members frequently report the following when using HGH Fragment 176-191:

  • Fat loss: Moderate fat reduction when combined with diet and exercise, typically noticed at 4-8 weeks
  • No anabolic effects: Users confirm the fragment does not produce muscle growth or GH-related side effects
  • No blood sugar impact: Users report stable blood glucose, consistent with published data
  • Localized fat reduction: Some users claim enhanced fat loss near injection sites, though this is not supported by published evidence
  • Subtle effects: Many users report effects are more modest than expected based on community hype

Important Caveats#

  • The largest clinical trial (AOD-9604) failed to show significant weight loss
  • Most clinical data is on AOD-9604, not the unmodified fragment used by the community
  • Self-reported fat loss is difficult to separate from diet and exercise effects
  • Product quality and actual peptide content vary between vendors

Reconstitution and Storage Practices#

  • Reconstitution: 1-2 mL bacteriostatic water per 5 mg vial
  • Storage: Refrigerated at 2-8 degrees C after reconstitution
  • Shelf life: Use within 3-4 weeks of reconstitution
  • Injection timing: Morning fasted and/or pre-bed on empty stomach

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.

150+ peptide profiles ยท 30+ comparisons ยท 18 research tools

Already subscribed?

Frequently Asked Questions About HGH Fragment 176-191

Explore Further

โš ๏ธ

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.